Company ProfilePremium

Asian Petro Products and Exports Limited

Company Profile Analysis

Ticker: 524434.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Asian Petro Products and Exports Limited - Company showcase

Year Founded & Workforce

1991

14 Employees

Asian Petro Products and Exports Limited logo

Asian Petro Products and Exports Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Asian Petro Products and Exports Limited Overview

Asian Petroproducts and Exports Limited is a Vadodara-based micro-cap that was set up in 1991 to manufacture ethylene-oxide (EO) derivatives — ethanolamines (mono-, di- and tri-ethanolamine) and non-ionic ethoxylates — for refinery, fertiliser, textile, dye, pharmaceutical and detergent customers, and which describes itself as an early Indian producer of ethoxylates. After roughly a decade of near-dormancy (annual revenue below INR 2 crore through FY2019 and nil in FY2024), the company was recapitalised by its promoter family through warrants (2021–2023) and an INR 15.89 crore rights issue (late 2024), and has since rebuilt turnover to INR 67.5 crore in FY2026 and roughly INR 100 crore on a trailing-twelve-month basis. Its reported cost structure shows revenue is now overwhelmingly derived from low-margin trading of chemicals and plastic products rather than captive manufacturing. With a market value near INR 24 crore, a qualified audit opinion, and a further promoter-heavy preferential issue pending shareholder approval on 6 November 2026, it is best characterised as a promoter-controlled turnaround vehicle rather than an operating specialty-chemicals franchise.


The company's own description

In its FY2026 Management Discussion & Analysis (as reproduced by India Infoline), the company states, in substance, that it was incorporated in 1991, listed on BSE in 1994, began by manufacturing chemicals based on ethylene oxide, and regards itself as a pioneer of ethoxylate manufacture in India, serving refineries, fertiliser, textile, dye, pharmaceutical and detergent producers. It goes on to say that, as markets changed, it diversified into other chemical solutions, polymers and plastic products, with its major production breakthroughs occurring between 2002 and 2006; that its trading department has for many years been active in importing and exporting chemicals, allied products and plastic products; and that it subsequently began a trading business in plastic products and chemicals from its plant at Village Anjesar, Savli. The MD&A also states that infrastructure has been established to expand capacity from 4,000 MT to 10,000 MT, that the company reports a single "manufacturing" business segment, and that management expects business volumes to increase in the current year, barring unforeseen circumstances.

The rights-issue profile (Chittorgarh, 2024) adds that the plant sits on a 25-hectare site and that management's stated future strategy centres on brand equity, specialty formulations, geographic expansion and collaboration with technical experts.

Independent characterisation

The reported numbers tell a materially different story from the "manufacturing" self-description. In FY2023, INR 15.92 crore of the INR 16.79 crore expense base was "purchase of traded goods" against revenue of INR 16.66 crore. In FY2025, aggregator data codes INR 41.67 crore of costs as raw-material consumption — exactly equal to revenue of INR 41.67 crore — which implies a pass-through rather than value-adding conversion. In FY2026, the quarterly breakdowns for Q1–Q3 show cost lines labelled "purchase of traded goods" of INR 4.68 crore, INR 43.17 crore and INR 8.64 crore against revenue of INR 4.71 crore, INR 43.71 crore and INR 9.08 crore respectively. Cost of revenue was INR 66.48 crore against revenue of INR 67.50 crore for the full year (stockanalysis.com), a gross margin of roughly 1.5%. A manufacturing operation converting purchased EO or fatty alcohols into ethoxylates would ordinarily earn a materially higher conversion margin; a near-100% cost-to-revenue ratio is characteristic of commodity trading or back-to-back procurement.

The most defensible characterisation is therefore: (i) a legacy EO-derivatives manufacturer whose plant has, on the evidence of a near-zero depreciation charge (INR 0.00–0.03 crore per year in FY2022–FY2026) and fixed assets of roughly INR 2 crore, either been fully depreciated or largely idle; (ii) currently operating predominantly as a trader of chemicals and plastic products; with (iii) an optionality claim on reviving manufacturing using the expansion-ready infrastructure at Anjesar. Screener's AI extraction layer tracks premium-gated metrics titled "Trading sales as % of total revenue" and "Bond-to-Bond sales as % of total revenue", which suggests the annual report contains disclosures on trading share and customs-bonded (bond-to-bond) transactions; the values were not publicly accessible.

Business and revenue model

DimensionAssessmentBasis
Product vs service vs subscription vs licensing~100% product sales (physical goods); no service, subscription or licensing revenue disclosedRevenue from operations line only; no other operating revenue in FY2025–FY2026 (stockanalysis.com)
Manufacturing vs trading splitNot publicly disclosed; cost structure indicates trading is dominantQuarterly "purchase of traded goods" ≈ revenue (Vogue/BFSL)
Value-chain positionDownstream of EO producers (EO in India is produced by large integrated refiners/petrochemical companies); upstream of formulators in detergents, textiles, agrochemicals, oilfield and personal careProduct list; industry structure
Customer typesIndustrial B2B buyers in refineries, fertilisers, textiles, dyes, pharmaceuticals, detergents, personal careCompany description; Screener summary
Customer concentration——
Pricing modelSpot/contract commodity pricing; not disclosed—
Working-capital modelSupplier-financed: payable days 148 vs debtor days 45 and inventory days 7 in FY2026, cash conversion cycle −97 daysScreener ratios

End-markets served

The company names refineries (ethanolamines are used in gas sweetening and corrosion control), fertilisers, textiles and dyes (ethoxylates as wetting, levelling and scouring agents), pharmaceuticals, and detergents/personal care (lauryl alcohol ethoxylates and stearic acid ethoxylates as non-ionic surfactants and emulsifiers). It has also named plastic products as a traded category. No revenue split by end-market is disclosed.

Strategy

Stated corporate strategy (themes from filings)

The company's stated strategy, as expressed across the FY2026 MD&A and the 2024 rights-issue materials, has five themes, paraphrased here: (1) increasing business volumes in the current year, subject to unforeseen circumstances; (2) using already-established infrastructure to expand manufacturing capacity from 4,000 MT to 10,000 MT; (3) growing sales through brand equity and specialty formulations; (4) geographic expansion; and (5) collaboration with technical experts, with an emphasis on quality control. The MD&A also contains a generic macro statement to the effect that industrial targets will be hard to achieve unless the government lowers interest rates and improves availability of funds. The company holds no investor days and provides no strategy presentation.

Strategic initiatives announced in the last 24 months (Oct 2024 – Oct 2026)

DateInitiativeDetailStatus
Oct–Dec 2024Rights issue (11:6 at INR 10)INR 15.89 crore raised; objects: repay promoter unsecured loans, fund working capital, general corporate purposesCompleted; capital INR 24.56 crore
Dec 2024 onwardRevival of trading/sales operationsRevenue restarted in Q3 FY2025 and scaled to INR 67.5 crore in FY2026Ongoing
FY2026Statutory auditor changeMaheshwari & Co. replaced D B S & AssociatesCompleted
30 May 2026Internal audit functionInternal auditor appointedCompleted
FY2025 auditor noteAccounting software upgradeCompany stated it was upgrading software to add audit-trail (edit log) functionalityStatus not disclosed
Sep 2026Preferential issue (first attempt)Board meeting scheduled for 9 Sep, rescheduled (8 Sep notice), and on 11 Sep the decision was deferred for further deliberationSuperseded
15 Oct 2026Capital restructuring via preferential allotment96 lakh equity shares to promoters to convert unsecured loans (INR 9.6 crore); 1 crore convertible warrants to promoter group (up to INR 10 crore); 40 lakh equity shares to public-category investors (INR 4 crore); all at INR 10; total up to INR 23.6 crore; relevant date 7 Oct 2026EGM 6 Nov 2026

No partnerships, sustainability commitments, cost-reduction programmes with targets, or new business launches have been announced.

Medium-term targets and guidance

None. The company provides no quantitative revenue, margin, capacity-utilisation or return targets. The only forward-looking statement is the qualitative expectation of higher business volume. The 10,000 MT capacity figure is an infrastructure statement, not a dated commissioning target, and no capex budget for it has been disclosed.

Analytical view of the strategy

The pending preferential issue is the single most consequential strategic act. If fully approved and the warrants are exercised, share count rises from 2.46 crore to approximately 4.82 crore (+96%). Derived promoter holding would rise from ~1.40 crore shares (56.87%) to ~2.36 crore of 3.82 crore shares (~61.8%) after the equity tranches, and to ~3.36 crore of 4.82 crore shares (~69.7%) on full warrant conversion. Pricing at par (INR 10) is close to the current market price (~INR 9.8), so dilution is not at a steep discount, but it consolidates promoter control further while converting promoter debt into permanent capital. The fresh cash component (INR 4 crore immediately from public allottees plus warrant money, typically 25% upfront and 75% on conversion under SEBI ICDR) would fund working capital for the trading book, and potentially the dormant capacity expansion.

Products & Services

The company does not publish product specifications, capacities by product, price lists or launch dates. The catalogue below combines the company's disclosed product list (MarketsMojo company CV, TradingView, Screener) with general industry descriptions of each chemical's function. Specifications are generic industry characteristics, not company-specific data.

Ethanolamines (EO + ammonia derivatives)

ProductDescription and typical functionTarget customers (company-named industries)Company-specific specs / pricingLaunch year
Monoethanolamine (MEA)Primary amine; used in acid-gas (H2S/CO2) scrubbing, as a corrosion inhibitor and as a chemical intermediate. Screener's summary calls it "monoethanolamide" — likely a transcription varianceRefineries, fertilisers, detergents—Not disclosed (original 1990s portfolio)
Diethanolamine (DEA)Secondary amine; used in gas treating, as an intermediate for alkanolamides (detergent foam boosters) and in textile chemicalsRefineries, detergents, textiles——
Triethanolamine (TEA)Tertiary amine; used as a pH adjuster/emulsifier in personal care, cement grinding aid, textile and metalworking fluid additiveDetergents, personal care, textiles, pharmaceuticals——

Ethoxylates (EO + fatty substrate derivatives)

ProductDescription and typical functionTarget customersCompany-specific specs / pricingLaunch year
Ethoxylates of various molesNon-ionic surfactants whose hydrophilic–lipophilic balance is set by the number of moles of EO added; used as wetting agents, emulsifiers, dispersantsTextiles, dyes, agrochemicals, detergentsMole range not disclosedCompany claims pioneering status in Indian ethoxylate manufacture
Lauryl alcohol ethoxylatesC12 fatty alcohol ethoxylates; core non-ionic surfactant in household and industrial detergents and a precursor for sulphated surfactantsDetergents, personal care——
Stearic acid ethoxylatesFatty-acid ethoxylates (PEG stearates); emulsifiers and thickeners in personal care, textile softeners and lubricantsPersonal care, textiles, pharmaceuticals——

Diversified and traded categories

CategoryDescriptionStatus
Other chemical solutionsDiversification undertaken in the 2002–2006 period per MD&AProduct names not disclosed
PolymersNamed as a diversification areaProduct names not disclosed
Plastic products (trading)Traded from the plant premises; also imported/exported by the trading departmentCurrent principal revenue driver on cost-structure evidence; names, grades and volumes not disclosed
Chemicals (trading)Import, export and domestic trading of chemicals and allied productsVolumes and counterparties not disclosed

Brands, platforms and flagship offerings

No brand names, trademarks, or flagship SKUs are publicly disclosed. The 2024 rights-issue profile referred to a strategy of building "brand equity", but no brand has been named in any retrieved filing.

Financial Narrative

All figures INR crore, standalone, Ind AS, fiscal years ending 31 March. Primary sources: Directors' Reports (FY2023–FY2024 via India Infoline), BSE results as compiled by Vogue/BFSL (FY2021–FY2025), Screener/C-MOTS and stockanalysis.com/S&P (FY2026), company MD&A ratio table (FY2025–FY2026).

Income statement

Notes. FY2026 revenue: Screener's announcement summary of the BSE filing gives INR 6,750.30 lakh; InvestorFeed gives INR 6,695.30 lakh; stockanalysis.com gives INR 675.03 million. The INR 67.50 crore figure (matching two of three sources and the sum of reported quarters, INR 67.51 crore) is used. FY2026 other income and interest are sums of reported quarters; stockanalysis.com shows interest of INR 3.36 million (0.34 crore). FY2026 PAT of INR 120.99 lakh is from the company's MD&A. Gross profit is from stockanalysis.com (revenue less cost of revenue); its FY2022 revenue includes other revenue. EPS discrepancy: Vogue/BFSL shows FY2022 basic EPS −0.43 but diluted −0.03, and FY2023 basic 14.00 vs Directors' Report 0.14 — the FY2023 Directors' Report figure (INR 0.14) is used; Screener restates historic EPS for the rights issue (FY2024 −0.42, FY2022 −0.15), so per-share history is not comparable across sources.

Margins and growth

Revenue CAGR FY2022–FY2026 (4 years): approximately 273% per annum (from INR 0.35 crore to INR 67.50 crore) — mathematically correct but analytically meaningless given the near-zero base. The FY2023–FY2026 three-year CAGR is approximately 59%, matching Screener's 59%. The company's MD&A reports a net profit ratio of 1.81% for FY2026 versus −2.83% for FY2025; the small difference from the 1.8% above reflects the revenue denominator used. Screener reports an FY2022 OPM of −131%; the −134% above uses −0.47 operating profit from Research360 (Screener rounds to −0.46).

Quarterly trajectory (most recent eight quarters)

Source: Screener (C-MOTS). The prior-year quarters Q1–Q3 FY2025 had revenue of 0.00, 0.00 and 10.15 respectively. Note: a Business Standard-derived article describes Q1 FY2026 OPM as positive 3.82%; Screener shows −3.82% (operating profit −0.18 on revenue 4.71), which is arithmetically consistent — the article's sign appears erroneous. Q4 FY2026 profit was driven almost entirely by INR 1.19 crore of other income; operating profit was negative.

Trailing twelve months (Q2 FY2026–Q1 FY2027): revenue INR 100.50 crore; operating profit excl. OI INR −0.07 crore; other income INR 1.47 crore (matches Screener's flag); net profit INR 0.99 crore; EPS INR 0.40.

Balance sheet

Notes. Share capital and reserves FY2022–FY2025 from Vogue/BFSL; FY2026 reserves derived as FY2025 reserves plus FY2026 PAT (−12.80 + 1.21), consistent with Screener's rounded −12 and book value of INR 5.28 × 2.4558 crore shares = INR 12.97 crore. Borrowings FY2022–FY2024 are Screener's rounded figures; FY2025 and FY2026 borrowings are derived from the company's reported debt-equity ratios (0.08 and 0.11) multiplied by net worth, consistent with Screener's rounded "1". Cash, the short-/long-term debt split, and exact current assets/liabilities are not publicly disclosed in retrieved sources. Net working capital is derived from the company's current ratios (1.33 FY2025; 1.37 FY2026) applied to approximate current liabilities equal to other liabilities; treat as indicative only. Net worth was negative until the rights issue in FY2025.

Debt split and net debt. The short-term/long-term split of borrowings is not publicly disclosed. Net debt cannot be computed because cash is not disclosed. Screener's cash-flow data shows a net cash inflow of INR 8 crore in FY2025 (rights proceeds) and an outflow of INR 2 crore in FY2026, which suggests positive cash balances, but no balance-sheet cash figure was retrievable.

Cash flow

Source: Screener (rounded to whole crore). Capex approximated from investing outflows; FY2025 investing activity also included loans to and repayments from related entities. FY2025 financing inflow of ~INR 12 crore reflects INR 15.89 crore of rights proceeds net of repayment of promoter loans (a stated object of the issue). Cumulative FY2025–FY2026 operating cash burn of ~INR 5 crore occurred despite a reported profit in FY2026, reflecting working-capital build as trading volumes scaled.

Ratios

Notes. Company ratios are from the FY2026 MD&A table. ROE for FY2022–FY2024 is not meaningful because net worth was negative. ROA uses average total assets (Screener rounded figures), so FY2022–FY2024 values are approximate. ROIC derived as FY2026 EBIT incl. other income (1.57) × (1 − ~1% tax) ÷ invested capital (equity 12.97 + debt 1.43); excluding other income, ROIC is negative because operating EBIT was −0.08. Net debt/EBITDA is not computable (cash undisclosed; operating EBITDA negative). Debtor/inventory/payable days from Screener.

Commentary on trends, inflections and drivers

Revenue. The five-year revenue series is not a growth trend in the conventional sense; it is a sequence of restarts. FY2022's INR 0.35 crore and FY2024's nil revenue bracket an FY2023 burst of INR 16.66 crore that was almost entirely traded goods. The genuine inflection began in Q3 FY2025, coinciding with the rights issue: once the company had INR 15.89 crore of fresh equity and a positive net worth, it could carry working capital and supplier credit, and quarterly revenue moved into a INR 5–44 crore range. Quarterly volatility remains extreme (Q2 FY2026 INR 43.71 crore versus Q3 FY2026 INR 9.08 crore), which is consistent with lumpy, transaction-by-transaction trading rather than recurring production-led sales.

Margins. At the operating level, the company has not earned a meaningful positive margin in any year of the series. FY2026 operating profit excluding other income was approximately break-even (−INR 0.08 crore). The FY2026 reported profit of INR 1.21 crore is attributable to other income of INR 1.65 crore, of which INR 1.19 crore fell in Q4 FY2026. The nature of this other income (interest, write-backs, foreign-exchange gains, or one-off items) is not disclosed in retrieved sources and is a key diligence item; Screener flags the dependency explicitly.

Cost base. Employee costs have risen from INR 0.29 crore (FY2022) to roughly INR 0.65–0.68 crore, and "other expenses" from INR 0.19 crore to INR 0.95 crore (FY2025), reflecting the cost of maintaining listing, compliance and a trading operation. Against a gross margin of ~1.5%, the company needs annual revenue of roughly INR 100 crore merely to cover a INR 1.5 crore fixed cost base at the gross level — which is approximately where TTM revenue now sits.

Balance sheet. The rights issue converted a negative net worth of −INR 2.95 crore (FY2024) into +INR 11.76 crore (FY2025). Accumulated losses (reserves of −INR 11.59 crore) still consume nearly half of paid-up capital. Total assets jumped tenfold from ~INR 4 crore to ~INR 41 crore, funded mainly by trade payables (other liabilities ~INR 27–28 crore), which makes suppliers the company's principal financiers.

Cash flow. Operating cash flow turned negative as the business scaled (−INR 4 crore in FY2025, −INR 1 crore in FY2026). Screener's CFO/EBITDA ratios of 220% (FY2025) and 1,589% (FY2026) are mathematical artefacts of near-zero denominators and should be ignored. The October 2026 preferential plan — fresh cash of INR 4 crore from public investors, up to INR 10 crore from promoter warrants, and INR 9.6 crore of loan conversion — implies management expects further working-capital needs.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Segment Margins & Growth (%)

Segment metricFY2022FY2023FY2024FY2025FY2026

Single segment revenue (INR Cr)

0.3516.660.0041.6767.50

Segment pre-tax profit (INR Cr)

-0.300.15-1.04-1.181.24

Segment PBT margin (%)

-85.70.9—-2.81.8

YoY revenue growth (%)

-38.64,660.0-100.0—62.0

Contribution to total revenue (%)

100100100100100

Revenue by Segment

Activity proxyFY2022FY2023FY2024FY2025FY2026

Cost of goods as % of revenue

94.395.6—100.098.5

Employee cost (INR Cr)

0.290.490.550.680.65

Other expenses (INR Cr)

0.190.360.470.95—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

0.3516.660.0041.6767.50

Other income (INR Cr)

0.200.280.000.511.65

Gross profit (INR Cr)

0.100.71-0.04-0.191.03

Operating profit / EBITDA excl. other income (INR Cr)

-0.47-0.10-1.02-1.63-0.08

EBITDA incl. other income (INR Cr)

-0.270.18-1.02-1.121.57

Depreciation (INR Cr)

0.030.030.020.000.00

Operating income / EBIT incl. other income (INR Cr)

-0.300.15-1.04-1.121.57

Interest expense (INR Cr)

0.000.000.000.050.33

Pre-tax income (INR Cr)

-0.300.15-1.04-1.181.24

Tax (INR Cr)

0.000.040.000.000.01

Net income (INR Cr)

-0.300.11-1.04-1.181.21

EPS basic as reported (INR)

-0.430.14-1.20-0.480.49

EPS diluted as reported (INR)

-0.030.01-1.20-0.480.49

Dividend per share (INR)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

28.64.3—-0.51.5

Operating (EBITDA excl. OI) margin (%)

-134.3-0.6—-3.9-0.1

EBITDA margin incl. OI (%)

-77.11.1—-2.72.3

Net margin (%)

-85.70.7—-2.81.8

Revenue growth YoY (%)

-38.64,660.0-100.0—62.0

Income Statement and Per-Share Data (Quarterly)

MetricQ4FY2025Q1FY2026Q2FY2026Q3FY2026Q4FY2026Q1FY2027

Revenue (INR Cr)

31.524.7143.719.0810.0137.70

Operating profit excl. OI (INR Cr)

-0.48-0.180.050.07-0.02-0.17

Other income (INR Cr)

0.510.37-0.050.141.190.19

Interest (INR Cr)

0.050.050.050.110.120.12

PBT (INR Cr)

-0.020.14-0.050.101.05-0.10

Net profit (INR Cr)

-0.020.14-0.050.101.04-0.10

EPS (INR)

-0.010.06-0.020.040.42-0.04

OPM (%)

-1.52-3.820.110.77-0.20-0.45

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Equity share capital (INR Cr)

6.927.708.6724.5624.56

Reserves and surplus / other equity (INR Cr)

-8.95-10.58-11.62-12.80-11.59

Total equity / net worth (INR Cr)

-2.03-2.88-2.9511.7612.97

Total borrowings (INR Cr)

3240.941.43

Other liabilities incl. trade payables (INR Cr)

1232827

Total assets (INR Cr)

2244142

Fixed assets (INR Cr)

00222

Goodwill and intangibles (INR Cr)

00000

Net working capital (INR Cr, derived)

———8.610.2

Book value per share (INR)

———4.795.28

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Cr)

010-4-1

Investing cash flow (INR Cr)

00-20-1

Financing cash flow (INR Cr)

0-11120

Net cash flow (INR Cr)

0008-2

Capex (INR Cr, approx.)

00201

Free cash flow (INR Cr)

01-1-4-1

Dividends paid (INR Cr)

00000

Buybacks (INR Cr)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%)

———-26.799.79

ROA (%, derived)

-15.05.5-34.7-5.22.9

ROCE (%, company)

———-23.4912.60

ROCE (%, Screener)

-2119-166-1712

ROIC incl. other income (%, derived)

————10.8

Current ratio (x)

———1.331.37

Debt to equity (x)

———0.080.11

Interest coverage, EBIT incl. OI / interest (x)

———-22.44.8

Asset turnover (x, derived)

0.178.330.001.851.63

Net capital turnover (x, company)

———4.386.25

Trade receivables turnover (x, company)

———2.923.77

Trade payables turnover (x, company)

———2.992.52

Debtor days

1,78328—23945

Inventory days

00——7

Payable days

————148

Cash conversion cycle (days)

1,78328—239-97

Revenue by Region

RegionFY2024FY2025FY2026

Total revenue (INR Cr)

0.0041.6767.50

Share Price & Returns

HorizonReturnSource / note

1 year

+10%

Screener (to Oct 2026); Bajaj Finserv shows +1.16% to 14 Aug 2026

3 years (CAGR)

−5%

Screener

5 years (CAGR)

−25%

Screener

Since IPO

−16.4%

S&P via Simply Wall St (as of May 2025)

Valuation Multiples

MultipleAPELPeer referenceBasis

Market cap (INR Cr)

24.1

India Glycols ~6,762 (May 2026)

Screener; Arihant

P/E (TTM)

24.3x—

TTM EPS INR 0.40

P/B

1.86x

Value Research cited peer median P/B of 1.02x (Apr 2026)

Book value INR 5.28

EV/Sales (TTM)

~0.25x

—

EV ≈ market cap 24.1 + debt ~1.4 (cash undisclosed, so EV is an upper bound) ÷ TTM revenue 100.5

EV/EBITDA (TTM)

Not meaningful excl. OI (EBITDA −0.07); ~18x incl. OI (EBITDA ~1.40)

—

Derived

Dividend yield

0%—

No dividends

Capital Markets Data and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Shares outstanding (crore)

0.690.770.872.462.46

Paid-up capital (INR Cr)

6.927.708.6724.5624.56

Promoter holding (%)

51.1656.0856.1756.4256.87

Dividend per share (INR)

00000

Share Price & Returns by Date

DateInstrumentSizePriceAllotteesOutcome

30 Nov 2021

Convertible warrants

23,87,500

—

Promoter & promoter group

9,70,000 converted 13 Apr 2023; treatment of remaining 14,17,500 not disclosed (likely lapsed or converted earlier)

11 Nov – 5 Dec 2024

Rights issue 11:6

~1.59 crore shares; INR 15.89 crore

INR 10 (par)

Existing shareholders (record date 30 Oct 2024)

Completed; capital INR 8.67 crore → INR 24.56 crore

Proposed (EGM 6 Nov 2026)

Equity shares (loan conversion)

96,00,000

INR 10

Promoters

Pending

Proposed

Convertible warrants

1,00,00,000

INR 10

Promoter group

Pending

Proposed

Equity shares

40,00,000

INR 10

Public-category investors

Pending

Analyst Conclusions

Management guidance

Management offers only a qualitative expectation of higher business volume in the current year, barring unforeseen circumstances (FY2026 MD&A). No revenue, margin, capacity-commissioning or capex guidance exists. Consensus growth expectations: none (no analyst coverage).

Bull case

  1. The operating platform has been rebuilt and is scaling. Revenue went from nil (FY2024) to INR 67.5 crore (FY2026) to ~INR 100.5 crore TTM, and Q1 FY2027 revenue of INR 37.70 crore was 8x the prior-year quarter. At ~0.25x EV/Sales, any margin improvement would be highly accretive to a INR 24 crore market cap: a sustained 2% net margin on INR 100 crore would be INR 2 crore of profit, or ~INR 0.81 per share on the current base.

  2. Balance-sheet clean-up is under way. The 2024 rights issue restored positive net worth, and the proposed INR 9.6 crore promoter-loan conversion would eliminate the main interest-bearing liability, while fresh warrant money supports working capital without bank debt.

  3. Hidden asset value and manufacturing optionality. A 25-hectare EO-derivative site with infrastructure for 10,000 MT is carried at ~INR 2 crore of fixed assets. A restart of ethoxylate manufacturing, even partially, would lift gross margins from ~1.5% toward conversion-level margins earned by producers.

Bear case

  1. There is no operating profit. Operating profit excluding other income has been negative in every year from FY2022 to FY2026 and again in Q1 FY2027; FY2026's reported profit exists only because of INR 1.65 crore of undisclosed other income.

  2. Minority shareholders bear the dilution. The proposed issue would nearly double the share count and lift promoter ownership toward ~70% (derived), shrinking free float in a stock with no institutional holders, while the at-par pricing gives promoters cheap optionality via warrants.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorableWhat to watch
6 Nov 2026EGM vote on preferential issueApproval margin; any public-allottee identities; in-principle BSE approval
Nov 2026Q2 FY2027 resultsWhether revenue sustains above INR 30 crore per quarter and operating margin turns positive
OngoingWarrant subscription moneyUpfront 25% receipt and use of proceeds
FY2026 annual reportBasis for FY2026 qualification; nature of other income; promoter loan balance; trading vs manufacturing splitReconciliation of "debt-free" statement with INR 9.6 crore loan conversion
Feb 2027Q3 FY2027 resultsInterest cost after loan conversion
May 2027FY2027 audited resultsWhether the audit opinion becomes unqualified under the new auditor and internal-audit regime
Any timeCapex announcement for 10,000 MT capacityBudget, timeline, environmental clearances, EO supply arrangement
Any timeRelated-party transactionsFurther loans to Brijlaxmi or World Tradimpex entities

Analyst verdict

Asian Petroproducts and Exports Limited should not be analysed as a specialty-chemicals company. It is a promoter-controlled listed shell that has been recapitalised and put back to work, primarily as a trader of chemicals and plastic products, with a legacy ethylene-oxide-derivatives plant whose economic contribution is currently invisible in the accounts. The evidence is consistent across sources: cost of goods near 98–100% of revenue, depreciation close to zero, operating losses in every year of the five-year window, and a FY2026 profit that rests entirely on other income.

The revival has been real at the top line. Revenue has scaled from nothing to roughly INR 100 crore on a trailing basis, the 2024 rights issue repaired a negative net worth, and the supplier-financed working-capital model has allowed volume growth with limited equity. The separation of chair and MD, a clean secretarial compliance report, an auditor change and the appointment of an internal auditor indicate some effort at remediation.

Against that, the quality of information is the binding constraint. Two consecutive qualified audit opinions, tax-compliance lapses, an absence of internal audit and audit trails until recently, intra-group loans without repayment terms, and contradictory narrative statements (a "debt-free" claim alongside a proposed conversion of INR 9.6 crore of promoter loans) mean that investors cannot place high confidence in reported figures. The pending preferential issue will further concentrate ownership in the promoter family at par value.

At roughly INR 24 crore of market value, 1.9x book and 0.25x TTM sales, the stock prices in neither the asset optionality of the Anjesar site nor the governance discount fully; it is effectively a binary call on whether the promoters convert the plant and the fresh capital into a genuinely value-adding manufacturing business. Until the company delivers a positive operating margin for several consecutive quarters, an unqualified audit, and a funded capacity plan, the appropriate stance is to treat it as a speculative, high-risk micro-cap suitable only for monitoring, not as an investable operating franchise.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleCategoryTenure / key datesNotes

Jaykishor Chaitanyakishor Chaturvedi

Managing Director (DIN 00467706)

Executive, Promoter

MD per S&P data since Sep 2019 (earlier MD term to 2018); Chairman until 30 May 2024

Largest shareholder: 24.91% directly (61,18,554 shares); signs company filings

Jashwant Bhatt

Chairman

Independent (listed as independent director in 2022)

Appointed Chairman 30 May 2024; reappointed 30 May 2026

Chair/MD separation since May 2024

Siddharth Jaykishor Chaturvedi

Director

Non-independent, Promoter group

Listed as director since at least Mar 2022

Holds 8.73% (21,43,385 shares)

Nupur Chaturvedi

Director

Non-independent (promoter family)

Listed as director as of Mar 2022

—

Devindersingh Bhumra

Director

Independent

Appointed 1 Oct 2022

—

Ankur Jaykishor Chaturvedi

Chief Financial Officer

KMP, Promoter group

—

Holds 1.30% (3,18,192 shares)

Anjali Gurnani

Company Secretary & Compliance Officer

KMP

~7.2 years (S&P, Nov 2025)

—

Rajendra Kumar Singhal

Former Independent Director

Independent

Resigned 18 May 2022

Departure

“—” = not publicly disclosed.

Directors' Remuneration

PersonSalaryBonusStock / optionsTotalPeriod

Jaykishor Chaturvedi (MD)

INR 2.40 million (100% salary)

00

INR 2.40 million

Latest S&P-reported fiscal year (likely FY2025)

Company Secretary

———

INR 0.555 million

Same

“—” = not publicly disclosed.

Board & Management Changes

DateChangeContext

18 May 2022

Rajendra Kumar Singhal resigned as independent director

Reason not disclosed

1 Oct 2022

Devindersingh Bhumra appointed independent director

Board refresh

30 May 2024

Jashwant Bhatt appointed Chairman; J. K. Chaturvedi relinquishes chair

Separation of chair and MD

FY2026 (by Feb 2026)

Statutory auditor change from D B S & Associates to Maheshwari & Co.

Followed FY2025 qualified opinion; reasons not disclosed in retrieved sources

30 May 2026

Jashwant Bhatt reappointed; internal auditor appointed

Addresses FY2025 CARO observation that internal audit was not implemented

Shareholding Trend

Holder categoryFY2022FY2023FY2024FY2025FY2026

Promoter and promoter group (%)

51.1656.0856.1756.4256.87

Public (%)

48.8443.9243.8343.5843.15

FII (%)

00000

DII / mutual funds (%)

00000

Number of shareholders

14,13114,38115,09116,29416,461

Major Shareholders

RankHolderCategorySharesStake (%)
1

Jaykishor Chaturvedi

Promoter

61,18,554

24.91
2

Chaturvedi (HUF) / J. K. Chaturvedi (HUF)

Promoter group

26,39,370 – 27,49,874

10.75 – 11.20

3

Siddharth Jaykishor Chaturvedi

Promoter group

21,43,385

8.73
4

Kailashben Ashokkumar Patel

Public

14,12,480

5.75 (MarketsMojo also cites 6.22%)

5

Brijlaxmi Leasing and Finance Limited

Classified as promoter by Vogue/BFSL EOD data; not in Emkay's promoter list

~14,10,000

5.74
6

World Tradeimpx Ltd

Promoter group (per Bajaj Finserv/Vogue)

12,24,500

4.99
7

Ashish Chugh

Public

5,00,000

2.04
8

Ankur Jaykishor Chaturvedi

Promoter group

3,18,192

1.30
9

Glaston Mario Menezes

Public

2,51,110

1.02
10

Chaitanya K Chaturvedi

Promoter group

00.00

Competitive Landscape

Key Competitors

#CompetitorOverlap with APELFY2026 revenue (INR Cr)Positioning relative to APEL
1

Galaxy Surfactants Ltd

Fatty alcohol ethoxylates and other non-ionic/anionic surfactants for home and personal care

5,248 (consolidated)

Scale leader in Indian oleochemical surfactants; ~78x APEL's revenue

2

India Glycols Ltd

EO and EO derivatives (ethoxylates, glycols), bio-based ethoxylates/amines

4,211 (consolidated sales, Business Standard); Anand Rathi shows net sales of 9,827 on a different basis

Integrated EO producer from bio-ethanol; dominant domestic EO-derivative player

3

Balaji Amines Ltd

Amines (methyl/ethyl amines and derivatives) — adjacent to ethanolamines

1,425 (Business Standard); 1,454 consolidated per other filing summaries

Specialist amine producer; zero standalone debt

4

Reliance Industries (petrochemicals)

Domestic EO/MEG producer; upstream supplier to ethoxylators

—

Feedstock supplier, not a direct product competitor

5

Indian Oil Corporation (Panipat petrochemicals)

Domestic EO/MEG producer

—

Feedstock supplier

6

BASF India Ltd

Imported/locally marketed ethanolamines and surfactants

—

Global major with distribution in India

7

Clariant Chemicals (India) Ltd

Specialty surfactants and ethoxylates for textiles and agro

—

Specialty-focused MNC subsidiary

8

Alkyl Amines Chemicals Ltd

Amines and derivatives

—

Specialist amines producer

9

Diamines & Chemicals Ltd

Ethyleneamines

—

Small listed amines producer

10

Unlisted Indian ethoxylators and chemical traders (Gujarat/Maharashtra clusters)

Ethoxylates and traded chemicals/plastics

—

Most direct competitors for APEL's current trading model

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricAPELGalaxy SurfactantsIndia GlycolsBalaji Amines

Revenue (INR Cr)

67.55,248.34,211.41,425.0

Revenue growth YoY (%)

62.024.311.82.0

Operating / EBITDA margin (%)

-0.1 (excl. OI)

~9.4 (EBITDA 4,974 mn / revenue 52,704 mn)

—18.63

Net profit (INR Cr)

1.21267.38

292.76 (consolidated)

167.20

Net margin (%)

1.85.1

~7.0

~11.7

Market cap (INR Cr)

~24

—

~6,762 (May 2026)

—

Company Snapshot

$7.8M

Revenue

14

Employees

1991

Founded

Vadodara, India

Headquarters

SWOT Analysis

Strengths

  • Restored solvency. Net worth moved from −INR 2.95 crore (FY2024) to +INR 12.97 crore (FY2026) following the INR 15.89 crore rights issue (FY2025 CARO; Section 6.4).
  • Revenue traction. Revenue rose from nil in FY2024 to INR 41.67 crore in FY2025 and INR 67.50 crore in FY2026 (+62%), and TTM revenue reached ~INR 100.5 crore by June 2026 (Screener).
  • Committed promoter capital. Promoters have injected capital three times in five years (23.875 lakh warrants in Nov 2021; rights in Nov–Dec 2024; INR 9.6 crore loan conversion plus up to INR 10 crore of warrants proposed Oct 2026).
  • Physical asset optionality. A 25-hectare plant site at Anjesar with infrastructure stated to support capacity expansion from 4,000 MT to 10,000 MT (FY2026 MD&A; Chittorgarh).
  • Supplier-financed working capital. FY2026 payable days of 148 against debtor days of 45 and inventory days of 7 produce a −97-day cash conversion cycle (Screener).
  • Low formal leverage and no pledge. Debt-equity of 0.11x (FY2026 MD&A), no pledged promoter shares (MarketsMojo), and no lender defaults or wilful-defaulter status (FY2025 CARO ix).

Weaknesses

  • No operating margin. Operating profit excluding other income was negative in every year from FY2022 to FY2026 (−0.47, −0.10, −1.02, −1.63, −0.08 INR crore) and in Q1 FY2027 (−0.17).
  • Profit dependent on other income. FY2026 PAT of INR 1.21 crore relied on INR 1.65 crore of other income, INR 1.19 crore of it in Q4 FY2026 (Screener).
  • Qualified audit opinions. FY2025 qualified for TDS and Ind AS 19 non-compliance; FY2026 also qualified; Q3 FY2026 review carried an emphasis of matter on GST/TDS.
  • Internal-control deficits. No internal audit in FY2025 (CARO xiv), accounting software without audit trail (auditor's Rule 11(g) note), and an internal-financial-controls annexure that referenced a "disclaimer of opinion" and March 2024 dates — inconsistent drafting within the FY2025 report.
  • Trading economics masquerading as manufacturing. Cost of goods at ~98.5% of revenue in FY2026 contradicts the "manufacturing segment" description.
  • Accumulated losses. Reserves of approximately −INR 11.6 crore still erode nearly half of INR 24.56 crore paid-up capital.

Opportunities

  • Capacity revival. Activating idle infrastructure to reach the stated 10,000 MT could convert low-margin trading into higher-margin ethoxylate production (FY2026 MD&A).
  • Fresh capital. The pending preferential issue could deliver up to ~INR 14 crore of new cash (INR 4 crore from public allottees plus up to INR 10 crore of warrant money) to fund working capital or capex (EGM notice, Oct 2026).
  • Deleveraging via conversion. Converting INR 9.6 crore of promoter unsecured loans to equity would reduce interest costs, which rose to INR 0.33 crore in FY2026 from INR 0.05 crore.
  • Specialty surfactant demand. Peer Galaxy reported 27% growth in Indian specialty ingredients in FY2026, indicating demand for differentiated non-ionics.
  • Bio-based and green chemistry. India Glycols reports bio-based amines growth and a green amine supply relationship with a global cosmetics major, showing customer appetite for sustainable EO derivatives that a small ethoxylator could address via toll manufacturing.
  • Remediation upside. Appointment of an internal auditor (30 May 2026) and a new statutory auditor create a path to an unqualified opinion, which would broaden the investor base.

Threats

  • Feedstock volatility. Fatty alcohol prices rose ~45% year on year to about USD 2,800/MT in Q2 FY2026 (Galaxy), squeezing non-integrated ethoxylators.
  • Scale disadvantage. Listed peers have revenues 21x–78x APEL's and EBITDA margins of ~9–19%.
  • Tax disputes. Disputed income-tax demands of ~INR 1.0 crore pending before ITAT/CIT(A) since 1995–2013 equal ~8% of FY2026 net worth (FY2025 CARO vii(b)).
  • Dilution and minority-shareholder risk. Full approval and conversion would nearly double share count to ~4.82 crore and lift promoter holding to ~70% (derived), reducing free float.
  • Regulatory/compliance exposure. Persistent TDS and GST reconciliation issues across FY2025 and FY2026 risk interest, penalties and late fees (TDS late-filing fees and interest of ~INR 1.58 lakh already outstanding at FY2025).
  • Logistics and geopolitics. Middle East disruption in 2026 hit chemical supply chains (cited by Galaxy and Balaji Amines), which affects import-dependent trading flows.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
12 May 2025Share price at INR 8.36, down 42.5% over one year, 52-week range INR 7.76–27.45 (S&P)Post-rights de-rating from the 2024 speculative high
30 May 2025FY2025 audited results: revenue INR 41.67 crore, loss INR 1.18 croreFirst full year of revived revenue
30 May 2025Auditor (D B S & Associates) issues qualified opinion: TDS non-compliance and Ind AS 19 non-complianceReporting-quality red flag
30 May 2025CARO discloses loans to Brijlaxmi Leasing & Finance (INR 107.09 lakh), World Tradimpex (INR 9.00 lakh), Brijlaxmi Infotech (INR 0.66 lakh) without repayment schedules; disputed income-tax demands ~INR 1.0 crore; no internal audit; no audit-trail softwareGovernance and control weaknesses
13 Aug 2025Q1 FY2026 results: revenue INR 4.71 crore, PAT INR 0.14 crore (other-income driven)Return to profit at the net level
Sep 2025Shareholding: promoters 56.42%; 16,522 shareholdersStable control
Nov 2025Q2 FY2026 results: record revenue INR 43.71 crore, loss INR 0.05 croreScale achieved but no margin
Dec 2025Shareholding: promoters 56.62% (Screener) / 56.41% (Emkay); 17,45,500 promoter shares locked inMinor creeping acquisition
29 Dec 2025Share at INR 10.75; P/E −68.3x, P/B 2.12x (ICICI Direct)Valuation on loss-making TTM
9 Jan 2026Reg. 74(5) SEBI (DP) compliance certificate filedRoutine
21 Jan 2026Q3 shareholding pattern filedRoutine
8 Feb 2026Board meeting intimation for Q3 resultsRoutine
14 Feb 2026Q3 FY2026 results: revenue INR 9.08 crore, PAT INR 0.10 crore; limited review by Maheshwari & Co. with emphasis of matter on GST and TDS compliance pending reconciliationAuditor change visible; compliance issues persist
Mar 2026Shareholding: promoters 56.87%Promoter creeping up
2 Apr 2026Share at INR 8.20; market cap INR 20 crore; 52-week range INR 7.00–11.20 (Value Research)Near cycle lows
16 Apr 2026Reg. 74(5) compliance certificateRoutine
26 May 2026Board meeting intimation for FY2026 results; trading window closed to 1 Jun 2026Routine
29 May 2026Annual Secretarial Compliance Report for FY2026 filed — no non-compliances notedPositive secretarial compliance signal
30 May 2026FY2026 audited results: revenue INR 6,750.30 lakh, PAT INR 120.99 lakh; qualified audit opinionFirst annual profit since FY2023, but qualified again
30 May 2026Jashwant Bhatt reappointed; internal auditor appointedPartial remediation of control weaknesses
Jun 2026Shareholding: promoters 56.87%, 16,459 shareholdersStable
Aug 2026Q1 FY2027 results: revenue INR 37.70 crore (+700% YoY), net loss INR 0.10 crore, OPM −0.45%Volume without profitability
Early Sep 2026Board meeting called for 9 Sep 2026 to consider preferential share issuanceCapital-raise intent signalled
8 Sep 2026Board meeting rescheduledProcess slippage
11 Sep 2026Board defers preferential issue for further deliberationTerms not yet settled
16–22 Sep 2026Register of members closed for AGMRoutine
22 Sep 202634th AGM held via video conferenceAnnual approval cycle
23 Sep 2026AGM proceedings filed following a BSE queryMinor disclosure-timeliness issue
1 Oct 2026Trading window closedPrecedes price-sensitive board meeting
~8–12 Oct 2026Intimation of 15 Oct board meeting to consider debt-to-equity conversion and fresh capitalRestructuring signalled
15 Oct 2026Board approves preferential issue up to INR 23.6 crore; EGM intimationMajor dilution event
16 Oct 2026EGM notice and revised EGM notice issued (96 lakh shares, 1 crore warrants, 40 lakh shares)Terms public
17 Oct 2026Newspaper publication of EGM notice; Reg. 74(5) certificateRoutine
19 Oct 2026Share closes at INR 9.81 (Screener)Market reaction muted

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 3.5 Mn in FY2022 to INR 675 Mn in FY2026.
Asian Petro Products and Exports Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations3.5166.60416.7675
Gross profit17.1-0.4-1.910.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Screener.in (C-MOTS data)— Quarterly results, P&L, balance sheet, cash flow, ratios, shareholding, announcements, annual-report links — FY2015–Q1 FY2027; price 19 Oct 2026 (screener.in)
  2. India Infoline — Auditors' Report— FY2025 qualified opinion, CARO annexure, tax disputes, related loans — FY2025 (signed 30 May 2025) (indiainfoline.com)
  3. India Infoline — Management Discussions— FY2026 MD&A: plant location, capacity, ratio table, debt-free statement — FY2026 (indiainfoline.com)
  4. India Infoline — Directors' Report— FY2024 and FY2023 financial highlights; secretarial auditor — FY2024 (live-next.indiainfoline.com)
  5. Vogue Commercial / BFSL — annual and quarterly results, live quote— P&L line items FY2021–FY2025; quarterly Dec 2024–Dec 2025; KMP; registered office; registrar — FY2021–Q3 FY2026 (voguestock.in)
  6. stockanalysis.com— FY2022–FY2026 revenue, cost of revenue, gross profit, interest — FY2022–FY2026 (stockanalysis.com)
  7. Simply Wall St (S&P Global Market Intelligence) — company information and management pages — Founding, listing date, MD compensation, tenure, analyst coverage, price history — 2025
  8. MarketsMojo (Motilal Oswal) — company CV, shareholding, results — Product list, registrar, capital structure, top holders, FY2026 growth rates, management as of 2022 — Mar 2022 – Jun 2026
  9. Emkay Global — shareholding pattern — 31 Dec 2025 shareholding detail, locked-in shares — Dec 2025
  10. Bajaj Finserv / Bajaj Markets — Top holders; price 14 Aug 2026 — 2026
  11. Voguestock EOD news items — Top five promoter holders Sep and Dec 2025 — 2025
  12. Equitybulls — 2021 warrants and 13 Apr 2023 conversion announcement — 2021–2023
  13. Chittorgarh.com — rights issue page — 2024 rights issue size, objects, plant site size, strategy statement — 2024
  14. Upstox; IPO Central — Rights ratio, record date, issue dates, promoter names — 2024
  15. ScanX — Q3 FY2026 board outcome, MD DIN, auditor Maheshwari & Co., emphasis of matter, CIN — Feb 2026
  16. Multibagg.ai — 34th AGM, book closure, preferential issue deferral, trading window — Sep–Oct 2026
  17. Whalesbook — 15 Oct 2026 board meeting agenda and preferential issue terms; EGM date; relevant date — Oct 2026
  18. InvestorFeed — KMP list; event feed; alternative FY2026 revenue figure — 2026
  19. AskFuzz (Business Standard-derived) — Q1 FY2027 results; India Glycols and Balaji Amines FY2026 results — 2026
  20. Zonebourse (S&P Capital IQ news) — Director appointments/resignations and Chairman change — 2020–2026
  21. EMIS — Employee count, alternative incorporation date — 2025–2026
  22. TradingView — IPO date, ISIN, product list, incorporation date
  23. Value Research; ICICI Direct; Business Standard; Business Today; Groww — Price, valuation and shareholding snapshots — Dec 2025 – Jul 2026
  24. Galaxy Surfactants — results via 5paisa, Anand Rathi, ConstructionWorld, FilingReader — Peer FY2026 revenue, PAT, EBITDA, segment revenue, market commentary — FY2026
  25. India Glycols — Arihant Capital Q4 FY2026 note; Anand Rathi — Peer revenue, profit, market cap — FY2026
  26. Balaji Amines — company press release (NSE), stockanalysis.com — Peer revenue, profit, OPM — FY2026

Items flagged as not publicly disclosed or not verifiable in this research cycle: cash and equivalents; short-/long-term debt split; geographic revenue; manufacturing vs trading split; R&D spend; patents; director ages, education and full current board list; complete FY2026 qualification text; nature of FY2026 other income; employee trend; customer concentration; product specifications and capacities by product; Indian end-market sizes; ESG ratings; credit ratings; debt maturity profile; status of the 14,17,500 unconverted 2021 warrants.

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.